Colinz Laboratories Ltd

As of June 30, 2026, Colinz Laboratories Ltd carries a market capitalization of 209.79M, placing it among publicly traded companies globally. Its enterprise value stands at 209.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Colinz Laboratories Ltd has 2.52M shares outstanding.

As of June 30, 2026, Colinz Laboratories Ltd trades at a trailing price-to-earnings ratio of 7.51.

As of June 30, 2026, Colinz Laboratories Ltd trades at an EV/EBITDA multiple of 6.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 209.79M versus a market cap of 209.79M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 915,102.36 in revenue per employee across its workforce of 63.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Colinz Laboratories Ltd recorded 6.33M in income tax expense. That works out to an effective tax rate of 18.46, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 34.30M, leaving 27.97M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Colinz Laboratories Ltd's stock has gained approximately 59.52% over the past 52 weeks. The 50-day moving average sits at 73.92, while the 200-day moving average is 61.52.

Over the twelve months ended June 30, 2026, Colinz Laboratories Ltd generated 58.11M in revenue and converted that into 27.97M in net income, yielding earnings per share of 11.10. EBITDA reached 30.97M, while operating income came in at 1.78M.

Over the twelve months ended June 30, 2026, Colinz Laboratories Ltd posted a gross margin of 69.53, reflecting its pricing power and cost economics. The operating margin of 3.06 and net profit margin of 48.13 provide insight into operational efficiency.